Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2014

Estimated Useful Lives

The estimated useful lives of these assets are as follows:

	Years
Building	13
Furniture and fixtures	7
Lab equipment	2–7
Computer hardware	5–7
Software	3–5

Ziopharm Oncology, Inc.

Summarized Unaudited Financial Information

Summarized unaudited financial information for Ziopharm for the three months ended March 31, 2014 and 2013 are as follows:

	Three months ended March 31,
	2014			2013
Revenues	$	200		$	200
Operating expenses		9,984			23,783
Loss from operations		(9,784	)		(23,583	)
Other		73			10,784
Net loss	$	(9,711	)	$	(12,799	)

Oragenics, Inc.

Summarized Unaudited Financial Information

Summarized unaudited financial information for Oragenics for the three months ended March 31, 2014 and 2013 are as follows:

	Three months ended March 31,
	2014			2013
Revenues, net	$	215		$	176
Gross profit		135			112
Loss from operations		(1,649	)		(1,736	)
Net loss	$	(1,641	)	$	(1,590	)